SPY441.40-4.34 -0.97%
DIA345.64-1.80 -0.52%
IXIC15,043.97-137.96 -0.91%

BRIEF-Kintor Gets NMPA Approval For Trials Of Proxalutamide To Treat COVID-19 In China

reuters.com · 09/01/2021 00:34
BRIEF-Kintor Gets NMPA Approval For Trials Of Proxalutamide To Treat COVID-19 In China

- Kintor Pharmaceutical Ltd KNTPF:

  • GOT APPROVAL FROM NMPA OF CHINA FOR TWO PHASE III CLINICAL TRIALS OF PROXALUTAMIDE FOR TREATING COVID-19 INFECTIONS IN CHINA

  • ONE PHASE III TRIAL TO BE CONDUCTED FOR PROPOSED TREATMENT OF MILD/MODERATE MALE COVID-19 PATIENTS IN CHINA, BRAZIL, MALAYSIA, PHILIPPINES

  • ANOTHER PHASE III TRIAL TO BE CONDUCTED TO TREAT HOSPITALISED COVID-19 PATIENTS IN US, CHINA, SOUTH AMERICA, EUROPE AND INDIA

Source text for Eikon: ID:nHKS4mBN7J

Further company coverage: KNTPF


((Reuters.Briefs@thomsonreuters.com;))